Greater Role of Cognitive Impairment Over Fatigue in Post-COVID-19 Quality of Life: A Post-Hoc Analysis of a Randomized Controlled Trial

Angela T.H. Kwan, MSc^{1,2}, <u>angela.kwan@mail.utoronto.ca</u> Moiz Lakhani, HBSc^{1,2}, <u>mlakh088@uottawa.ca</u> Gia Han Le, HBSc^{1,3}, <u>hanny.le@mail.utoronto.ca</u> Gurkaran Singh, MSc, MPH⁴, <u>gsingh93@student.ubc.ca</u> Kayla M. Teopiz, HBSc¹, <u>kayla.teopiz@mail.utoronto.ca</u> Ziji Guo^{1,5}, <u>ziji.guo@mail.utoronto.ca</u> Felicia Ceban, HBSc^{1,6}, <u>felicia.ceban@mail.utoronto.ca</u> Kanwarpreet Kaur Dhaliwal, BSc⁴, <u>komald7@student.ubc.ca</u> Sebastian Badulescu, HBSc^{1,5}, <u>sebastian.badulescu@mail.utoronto.ca</u> Roger Ho, MD, FRCPsych^{7,8}, <u>pcmrhcm@nus.edu.sg</u> Taeho Greg Rhee, PhD^{9,10}, <u>taeho.rhee@yale.edu</u> Bing Cao, PhD¹¹, <u>bingcao@swu.edu.cn</u> Giacomo d'Andrea, MD¹² <u>giacomo.dandrea1993@gmail.com</u> Roger S. McIntyre, MD, FRCPC^{1,5,13}*, <u>roger.mcintyre@bcdf.org</u>

Affiliations

1. Brain and Cognition Discovery Foundation, Toronto, ON, Canada

2. Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

3. Institute of Medical Science, University of Toronto, Toronto, ON, Canada

4. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

5. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada

6. Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada

7. Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

8. Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore

9. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

10. Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA

11. Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, 400715, P. R. China

12. Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio", Chieti, Italy.

13. Department of Psychiatry, University of Toronto, Toronto, ON, Canada

*Corresponding Author: **Dr. Roger S. McIntyre**, Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada Email: roger.mcintyre@bcdf.org, Phone Number: 416-669-5279

ABSTRACT

Background

Post COVID-19 Condition (PCC) is a common and debilitating condition with significant reports of fatigue and psychosocial impairment globally. The extent to which cognitive symptoms and fatigue contribute to reduced quality of life in affected individuals remains clear.

Methods

This is a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial that evaluated the effect of vortioxetine on cognitive function in adults with PCC. The post-hoc analysis herein aimed to determine the overall effect of baseline cognitive function [as measured by the Digit Symbol Substitution Test (DSST)] and baseline fatigue severity [as measured by the Fatigue Severity Scale (FSS)] on baseline health-related quality of life (HRQoL) [as measured by the 5-item World Health Organisation Well-Being Index (WHO-5)].

Results

A total of 200 participants were enrolled in the primary trial. Due to missing baseline data, our statistical analysis included baseline measures of 147 individuals. Our generalized linear model analysis revealed a significant positive correlation between DSST-measured objective cognitive function and self-reported WHO-5-measured HRQoL ($\beta = 0.069, 95\%$ CI [0.006, 0.131], p = 0.032). In contrast, our analysis revealed a significant negative correlation between FSS and WHO-5 scores ($\beta = -0.016, 95\%$ CI [-0.021, -0.011], p < 0.001). The beta-coefficient ratio ($\beta_{DSST}/\beta_{FSS} = 0.069/0.016$) is calculated as 4.313.

Conclusions

Overall, we observed that increased cognitive function was associated with increased HRQoL at baseline in adults with PCC. Moreover, we observed that increased severity of fatigue symptoms was associated with decreased HRQoL at baseline in adults with PCC. Furthermore, we observed that an improvement in cognitive function would have a four-fold greater impact on HRQoL than the effect generated by improvement in fatigue.

Keywords: COVID-19; Post-COVID Condition (PCC); Cognitive Function; Digit Symbol Substitution Test (DSST); World Health Organization Wellbeing Scale, 5-item (WHO-5); Health-Related Quality of Life (HRQoL); fatigue; Fatigue Severity Scale (FSS); Functional Impairment; Public Health

INTRODUCTION

Post COVID-19 condition (PCC) is a widespread, debilitating, and severe phenomenon.¹ The World Health Organization (WHO) defines PCC as a condition that occurs three months following confirmed coronavirus disease 2019 (COVID-19) infection, even after the acute infection resolves, and cannot be attributed to another diagnosis.² Approximately 10-20% of persons infected with COVID-19 meet the criteria for PCC.^{3,4} PCC is a heterogeneous group of disorders involving multiple organ systems.⁵ Additionally, cognitive impairment (e.g., brain fog) and fatigue are two of the most common features of PCC.^{1,6} Approximately 32% of individuals who experienced PCC reported fatigue, and 22% reported cognitive decline.¹

Cognitive impairment and fatigue are relevant to the health-related quality of life (HRQOL) and functioning of individuals with PCC; however, the extent of contribution from each domain is under-studied.^{1,7,8} Understanding their respective contributions to HRQOL holds implications for early interventions, the discovery and development of treatments, clinical care planning, and the characterization of mechanistic models in PCC. In this post-hoc study of a randomized controlled trial, we sought to determine the respective impacts of objective cognitive function (e.g., motor speed, attention, and visuoperceptual functions) and fatigue on measures of HRQOL in individuals with PCC.

MATERIALS AND METHODS

Study Design and Participants

Herein we conducted a post hoc analysis of a randomized, double blind, placebo-controlled clinical trial investigating the efficacy of vortioxetine in the treatment of cognitive symptoms in adults with PCC. The data and methodology reported herein was obtained from the primary trial which is published elsewhere.⁹ The primary trial was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki.^{10,11} The primary trial was registered on Clinicaltrials.gov (NCT05047952). The trial design was approved by Advarra, a local research ethics board (REB), that complies with Health Canada regulations, (IRB #00000971). Study recruitment took place in Canada from November 2021 to January 2023. Methods of participant recruitment included media advertisements (e.g., Facebook, Twitter, Instagram, and/or print) or referrals by medical practitioners. Written informed consent was obtained before participation from all eligible participants.

The eligibility criteria for the primary trial included: persons aged ≥ 18 years who were residing in Canada at the time of the study, able to provide documentation of WHO-defined PCC symptoms (i.e., symptoms of COVID-19 occurring within 3 months of acute SAR-CoV-2 infection and persisting for at least 2 months after resolution of acute infection with no other explanation), able to provide documentation of a positive severe acute respiratory syndrome coronavirus 2 (SARS \Box CoV \Box 2) test (i.e., antigen, serology, and/or PCR). Alternatively, participants without a documented positive SARS-CoV-2 test who were determined to have a probable SARS-CoV-2 infection (such as a prior diagnosis of acute COVID-19 from a healthcare provider or a clinical diagnosis from the study physician) were also deemed eligible. Moreover, participants were required to provide written informed consent at the time of screening/baseline in order to be eligible for the study.

Eligible participants that were using other antidepressants at the time of the study were instructed by the study physician to cease their antidepressant medication for a minimum of 2-4 weeks before the baseline assessment. Additionally, eligible participants were informed via consent forms that the safety and/or efficacy effects of combining the study medication with another antidepressant remains investigational. Individuals who met any of the exclusionary criteria were excluded from study participation (**Supplementary Materials, Table S1**).

Procedures

For the duration of an 8-week double blind treatment, 149 eligible participants were randomized (1:1) to receive vortioxetine (5-20 mg/d) or placebo. From weeks 1-2, participants in the vortioxetine group aged 18-65 received vortioxetine at 10 mg/d and participants aged 65+ in this group received vortioxetine at 5 mg/d. From weeks 3 to 8, participants aged 18-65 in the vortioxetine group received vortioxetine at 20 mg/d, and participants in this group aged 65+ received 10 mg/d. The vortioxetine and placebo capsules were identical in size and appearance.

Study visits occurred at baseline and weeks 2, 4, and 8. Due to public health recommendations in Canada during the time of the study, study visits were made available remotely via telephone or online platform (i.e., Zoom) to increase participant retention. Study visits were also made available in-person if preferred or required. A secure online platform (i.e., Ontario Telemedicine Network) was used to conduct visits with the study physician. A safety

visit during weeks 8 and 10 was offered to all participants. Participants who withdrew prior to study completion were scheduled for a follow up appointment at the earliest available date.

Outcome Measures

The primary outcome measure in the primary clinical trial was the effect of vortioxetine on cognitive performance as measured by the Digital Symbol Substitution Test (DSST) Pen/Paper Version and Online CogState Version as part of the CogState Online Cognitive Battery.⁹ The pen-paper version of the DSST was not completed by remote participants. At baseline, and weeks 2 and 8, the DSST was administered.

Additionally, multiple secondary outcome measures were collected in the primary trial, including fatigue as measured by the Fatigue Severity Scale (FSS) and health-related quality of life as measured by the 5-item World Health Organisation Well-Being Index (WHO-5). The FSS and WHO-5 were measured at baseline and weeks 2, 4 and 8. A complete list of all secondary outcome measures of the primary trial are reported in the primary paper.⁹

Statistical Analysis

All statistical computations were performed utilizing IBM SPSS Statistic software version 28.0.1.1 (15), with a significance level set at $\alpha = 0.05$. Descriptive statistics were expressed as frequency (%) for categorical variables; the mean [standard deviation (SD)] and median were utilized for continuously distributed variables with a normal distribution. Of the 149 enrolled participants, 11 (7.4%) completed the Pen/Paper Version of the DSST only; 78 (52.3%) completed only the CogState Version, and 60 (40.3%) completed both the Pen/Paper and Online CogState Version. For participants that completed both DSST versions, performances on the Pen/Paper and Online CogState Version were highly and significantly correlated (r = 0.588, *p* < 0.001). Further computations were performed using the combined DSST score as not all participants completed both the Pen/Paper and Online CogState DSST scores if they completed both Online CogState and Pen/Paper DSST. If the Online CogState DSST was not completed, participants' Pen/Paper DSST scores were included in the combined DSST scores. An intent-to-treat (ITT) analysis (i.e., including all randomized participants) was employed to assess DSST and FSS total scores at baseline.

To examine the correlation between objective cognition (DSST) and fatigue (FSS) on HRQoL, a generalized linear model (GLM) with a Poisson probability distribution was performed (WHO-5). Potential covariates identified were participant's age, sex, race, education, type of cognition test, suspected vs. confirmed COVID-19 diagnosis, and major depressive disorder (MDD) diagnosis.

RESULTS

Patient Characteristics

Baseline sociodemographic and clinical characteristics are described in **Table 1**. Of the 200 participants who provided signed informed consent, baseline analysis was conducted on data from only 147 participants due to missing information. No significant differences were observed between the groups for baseline characteristics (**Table 1**).

Greater Role of Cognitive Function Over Fatigue on Health-Related Quality of Life in Persons with Post-COVID-19 Condition

Results from the GLM analysis demonstrate a significant positive correlation between DSSTmeasured objective cognitive function and self-reported WHO-5-measured HRQoL ($\beta = 0.069$, 95% CI [0.006, 0.131], p = 0.032) (**Table 2**). In contrast, FSS ($\beta = -0.016$, 95% CI [-0.021, – 0.011], p < 0.001) shows a significant negative correlation with WHO-5 scores (**Table 2**). The beta-coefficient ratio ($\beta_{DSST} / \beta_{FSS} = 0.069 / 0.016$) is calculated as 4.313. This signifies that an improvement in cognitive function would have a four-fold greater impact on HRQoL than the effect generated by fatigue.

DISCUSSION

Herein, we found that objective cognitive impairment had a notably greater positive impact on HRQOL in individuals with PCC than fatigue. Both factors significantly contributed to reduced HRQoL, with cognitive impairment exerting a disproportionately larger influence.

It may be conjectured that the greater impact of cognitive impairment on HRQOL stems from the significant involvement of cognition in workplace/academic/social interactions, which is known to be more pronounced in individuals living with PCC.^{12,13} Moreover, such a decline in cognitive function may also lead to attenuated hedonic function, which would be predicted to

further decrease HRQoL in persons with PCC. For example, in other disease states such as MDD, it is established that cognitive function—specifically processing speed and executive function—and anhedonic function are dissociable phenomena but also highly overlapping.¹⁴ Our findings suggest that individuals with PCC should be screened for objective cognitive impairment and fatigue, allowing for a deeper comprehension of their contribution to HRQOL. It is important that treatment efforts correspond to their relative impact on HRQoL, involving strategies to preserve, regain, and protect cognitive function in persons with PCC. Our primary focus should be to address cognitive issues in individuals presenting with this concern.

Several methodological limitations impact interpretations and inferences drawn from our data. First, this was a post-hoc analysis based on data collected during the primary study, and our exploration of the relative contribution of cognitive functioning and fatigue to HRQoL was not pre-determined in the protocol. While we ruled out other medical conditions as the primary cause of presentation, it is possible that prior medical conditions affecting cognitive function might not have been disclosed. Our assessment of HRQoL in PCC also relied on self-reported data from the WHO-5. Different HRQoL assessments and functional neuroimaging measurements of cerebral oxyhemoglobin levels during DSST may yield different results.¹⁵ Furthermore, our sample was heterogenous and encompassed diverse factors such as acute COVID-19 severity, duration of PCC, number of prior COVID-19 infections, and the number and type of prior vaccinations.

CONCLUSION

Collectively, our findings show that cognitive impairment has a more pronounced impact on diminishing HRQoL than fatigue. Healthcare practitioners providing care to individuals with PCC should give precedence to therapeutic targets that wield the greatest influence on HRQoL. Furthermore, our data has implications in disease modeling and significantly informs the advancement of therapeutic strategies and development for individuals affected by PCC.

DISCLOSURES

Dr. Roger S. McIntyre has received research grant support from CIHR, GACD, National Natural Science Foundation of China (NSFC), and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp.

Felicia Ceban received fees from Braxia Scientific Corp.

Kayla M. Teopiz has received fees from Braxia Scientific Corp.

Dr. Roger Ho has received funding from the National University of Singapore iHeathtech Other Operating Expenses (A-0001415-09-00).

Dr. Taeho Greg Rhee was supported in part by the National Institute on Aging (NIA) (#R21AG070666; R21AG078972), National Institute of Mental Health (#R21MH117438), National Institute on Drug Abuse (#R21DA057540) and Institute for Collaboration on Health, Intervention, and Policy (InCHIP) of the University of Connecticut. Dr. Rhee serves as a review committee member for Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA) and has received honoraria payments from PCORI and SAMHSA. Dr. Rhee has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. Dr. Rhee serves as an advisory committee member for International Alliance of Mental Health Research Funders (IAMHRF). Dr. Rhee is currently a co-Editor-in-Chief of *Mental Health Science* and has received honoraria manually from the publisher, John Wiley & Sons, Inc.

FUNDING

The primary clinical trial was sponsored by the Brain and Cognition Discovery Foundation (BCDF) through an unrestricted research grant from H. Lundbeck A/S, Copenhagen, Denmark.

BCDF functions as a non-profit research organization. No specific grant from public, commercial, or not-for-profit funding organizations was given to the authors of this post hoc analysis.

DATA AVAILABILITY

The data and research materials that support the findings of this study are available from the corresponding author, R.S.M, upon reasonable request and will be anonymized.

REFERENCES

- 1. Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun*. 2022;101:93-135.
- Health Organization W. Клиническое определение случая состояния после COVID-19 методом дельфийского консенсуса. Accessed August 10, 2023. https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19condition-Clinical-case-definition-2021.1-rus.pdf
- 3. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis.* 2022;22(4):e102-e107.
- 4. Weatherley-Jones E, Nicholl JP, Thomas KJ, et al. A randomised, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome. *J Psychosom Res*. 2004;56(2):189-197.
- CDC. Post-COVID conditions: Information for healthcare providers. Centers for Disease Control and Prevention. Published June 22, 2023. Accessed July 3, 2023. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
- 6. Hartung TJ, Neumann C, Bahmer T, et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. *EClinicalMedicine*. 2022;53:101651.
- 7. Zhao S, Martin EM, Reuken PA, et al. Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study. *EClinicalMedicine*. 2024;68:102434.
- 8. Gross M, Lansang NM, Gopaul U, et al. What Do I Need to Know About Long-Covid-related Fatigue, Brain Fog, and Mental Health Changes? *Arch Phys Med Rehabil*. 2023;104(6):996-1002.
- 9. McIntyre RS, Phan L, Kwan ATH, et al. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. *Brain*. Published online November 4, 2023. doi:10.1093/brain/awad377
- 10. WMA declaration of Helsinki ethical principles for medical research involving human subjects. Accessed March 11, 2024. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
- 11. ICH Official web site : ICH. Accessed March 11, 2024. https://www.ich.org/page/efficacyguidelines
- 12. Miskowiak KW, Pedersen JK, Gunnarsson DV, et al. Cognitive impairments among patients in a long-COVID clinic: Prevalence, pattern and relation to illness severity, work function and quality of life. *J Affect Disord*. 2023;324:162-169.
- De Luca R, Bonanno M, Calabrò RS. Psychological and Cognitive Effects of Long COVID: A Narrative Review Focusing on the Assessment and Rehabilitative Approach. J Clin Med Res. 2022;11(21). doi:10.3390/jcm11216554
- 14. Subramaniapillai M, Mansur RB, Zuckerman H, et al. Association between cognitive function and

performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. *Compr Psychiatry*. 2019;94:152113.

15. Nakahachi T, Ishii R, Iwase M, et al. Frontal activity during the digit symbol substitution test determined by multichannel near-infrared spectroscopy. *Neuropsychobiology*. 2008;57(4):151-158.

TABLES

Table 1. Baseline characteristics of the intent-to-treat population (N = 147).

Characteristic	Placebo (<i>n</i> = 74)	Vortioxetine $(n = 73)$	<i>p</i> -value*
Age (Years), Mean (SD)	44.89 (12.14)	43.84 (12.35)	
Sex (Female), n (%)	55 (74.32)	56 (76.71)	0.736 ^b
Ethnicity (Caucasian), n (%)	55 (74.32)	57 (78.08)	0.263 ^b
Education, n (%)			0.390 ^b
< High School	0 (0)	1 (1.37)	
High School Graduate	4 (5.41)	8 (10.96)	
College/University Degree	10 (13.51)	7 (9.59)	-
Associates Degree	15 (20.27)	13 (17.81)	-
Bachelor's Degree	27 (36.49)	34 (46.58)	-
Graduate Degree	15 (20.27)	9 (12.33)	-
Professional Degree	3 (4.05)	1 (1.37)	-
Confirmed COVID Diagnosis, n (%)	59 (79.7)	57 (78.1)	0.807 ^b
MDD Diagnosis, n (%)	25 (33.78)	22 (30.14)	0.595 ^b
FSS (Total Score), Mean (SD)	51.84 (10.20)	49.78 (10.96)	0.083 ^a
Remote Assessment, n (%)	69 (93.24)	67 (91.78)	0.736 ^b
Combined DSST Z-score, Mean (SD) ^c	-0.194 (0.99)	0.0531 (1.01)	0.136 ^a

^aT-test

^bChi-square test

^cCombined DSST z-score defined as the equally weighted sum of the z-scores in the combined DSST (Pen/Paper plus Online CogState Version)

*Two-sided p values

IV Model		95% Confidence Interval			
	β	Lower	Upper	<i>P</i> -value	
Combined 1	DSST ^a		• •		
Cor	nbined DSST*	0.069	0.006	0.131	0.032
Age	<u>2</u> *	-0.001	-0.006	0.004	0.660
Sex		-0.028	-0.150	0.093	0.646
Rac	ce	-0.019	-0.043	0.004	0.111
Edu	ication*	0.066	0.023	0.109	0.003
Туј	be of Cognitive Test	0.340	0.114	0.566	0.003
Suspect 19*	ed vs. Confirmed COVID-	-0.180	-0.305	-0.054	0.005
MDD D	Piagnosis	0.074	-0.038	0.185	0.196
FSS					
Inte	ercept	3.162	2.680	3.644	< 0.001
FSS	5	-0.016	-0.021	-0.011	< 0.001
Age		-0.002	-0.006	0.002	0.384
Sex		-0.076	-0.199	0.047	0.225
Rac	ce	-0.002	-0.026	0.021	0.855
Edu	ication*	0.056	0.013	0.099	0.011
Suspect 19*	ed vs. Confirmed COVID-	-0.168	-0.293	-0.044	0.008
MDD D	Piagnosis	0.018	-0.097	0.132	0.762

Table 2. Generalized linear model of baseline cognition and fatigue on WHO-5 scores.

*p < 0.05

^aCombined DSST z-score defined as the equally weighted sum of the z-scores in the combined DSST (Pen/Paper plus Online CogState Version)

Abbreviations: DSST = Digit Symbol Substitution Test; FSS = Fatigue Severity Scale; IV = Independent Variable.